Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cassava Sciences, Inc. SAVA
$26.35
-$1.45 (-5.49%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1173366887.00000000
-
week52high
51.59
-
week52low
13.84
-
Revenue
-1800
-
P/E TTM
-12
-
Beta
-0.12975700
-
EPS
-1.91000000
-
Last Dividend
19.25000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 11 авг 2022 г. |
| B. Riley Securities | Buy | Buy | 24 янв 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 июл 2021 г. |
| B. Riley Securities | Buy | Buy | 23 июн 2021 г. |
| B. Riley FBR | Buy | 27 апр 2021 г. | |
| HC Wainwright & Co. | Buy | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cook Robert Christopher | A | 100000 | 100000 | 28 окт 2022 г. |
| FRIEDMANN NADAV | D | 40624 | 9376 | 03 окт 2022 г. |
| FRIEDMANN NADAV | A | 79910 | 9376 | 03 окт 2022 г. |
| ROBERTSON SANFORD | D | 0 | 2802 | 08 сент 2022 г. |
| ROBERTSON SANFORD | A | 1027567 | 2802 | 08 сент 2022 г. |
| Barry Richard | A | 186159 | 36159 | 23 авг 2022 г. |
| Kupiec James William | A | 2500 | 2500 | 23 авг 2022 г. |
| Schoen Eric | A | 19800 | 2500 | 12 авг 2022 г. |
| ROBERTSON SANFORD | A | 1024765 | 100000 | 12 авг 2022 г. |
| BARBIER REMI | D | 0 | 65368 | 06 июн 2022 г. |
Новостная лента
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
InvestorPlace
09 мая 2023 г. в 14:00
One of the stocks most in focus today for investors is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock have surged more than 15% as investors digest some promising news about the company's lead drug candidate.
Buy Cassava Sciences For Imminent Data Readout
Seeking Alpha
26 апр 2023 г. в 13:17
Buy Cassava Sciences For Imminent Data Readout.
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
GlobeNewsWire
26 апр 2023 г. в 09:12
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors who are registered to attend this conference.
Strong Small-Cap Insider Buys: Q1 2023
Seeking Alpha
26 апр 2023 г. в 00:15
Strong Small-Cap Insider Buys: Q1 2023.
3 Short-Squeeze Stocks to Keep on Your Radar
InvestorPlace
09 мар 2023 г. в 09:45
Short-squeezes have been making headlines in stock trading as an increasingly popular phenomenon. A short squeeze occurs when investors who have bet against a company's stock (by “shorting” it) are forced to buy back their shares to cut their losses.